The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.
Four Chinese biopharmaceuticals unveiled early data on respective cancer therapies at the American Society of Hematology (ASH) 2024 meet in San Diego, including Cstone Pharmaceuticals Co. Ltd.’s ...
最近的研究发现，一种名为ROR1的蛋白在套细胞淋巴瘤显著高表达，既然有ROR1这个列外的高表达，那就针对ROR1做了一款抗体偶联药VLS-101（也称之为MK ...
“We look forward to advancing our research of this investigational ROR1-directed antibody drug conjugate, which we believe has strong potential in multiple hematologic malignancies.” As ...
ROR1 is a cellular protein normally found in embryonic tissues, but absent in adult tissues. It does, however, occur in some malignant cells, raising the prospect of using it to deliver targeted ...
IND for IM-1021, a ROR1-targeted ADC, cleared by the FDA in fourth quarter of 2024. Novel solid-tumor ADC programs IM-1617, IM-1340 and IM-1335 are in preclinical development. Immunome ...
Lyell is focused on advancing next-generation CAR T cell therapies with the potential to deliver higher response rates and longer duration of responses for patients with hematologic malignancies and ...
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback